Browse Full Report with TOC at: http://www.researchmoz.us/glioblastoma-multiforme-therapeutics-in-asia-pacific-markets-to-2020-novel-therapeutic-approaches-target-high-unmet-need-in-newly-diagnosed-and-recurrent-gbm-report.html The report provides estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and in-depth analysis of the marketed and pipeline products.

1. Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and
Recurrent GBM
GBI Research, the leading business intelligence provider, has released its latest research: ‘Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets
to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM’, which provides in-depth analysis of the
Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides
estimates of market size for 2013, along with market forecasts until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, and
in-depth analysis of the marketed and pipeline products. The value of the GBM market in the APAC region amounted to an estimated $49.4m in 2013, and is
expected to register a Compound Annual Growth Rate (CAGR) of 11.5%, to reach $105.8m by 2020. The GBM market in India was the smallest of the APAC
markets in 2013, but is expected to experience the highest growth rate in the forecast period, at a CAGR of 14.4%, due to having the highest number of promising
candidates in the pipeline. Japan currently has the largest share of GBM market in the APAC region, at 48%, and is expected to experience healthy growth during
the forecast period at a CAGR of 13.8%. The existing treatment landscape is bleak for both newly diagnosed and recurrent GBM, with temozolomide alone
serving as the standard of care after surgery and radiation. For first-line treatment Rindopepimut, a novel vaccine, is in late-stage development in India and
Australia, but it is limited to EGFRvIII patients. There are two strong candidates in the current pipeline for second-line treatment: Avastin and Cotara. Avastin is
the first and only targeted therapy for newly diagnosed GBM, is already approved as second-line treatment in Australia and Japan, and is in Phase III
development in China and India. Cotara is a single-infusion drug with a novel delivery route, which is in Phase II development in India. The expected launch of
these three drugs is the key driver for growth in APAC GBM market. As all are expensive, even a modest uptake will increase the annual cost of therapy, and
subsequently the market size.
Scope
A brief introduction to GBM, including disease pathogenesis, risk factors, diagnosis, treatment options and algorithm In-depth analysis of major marketed
products, covering product performance, life-cycle, and a heat map depicting comparative analysis of safety and efficacy parameters A comprehensive review of
the GBM pipeline – including individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period
– analyzed on the basis of phase distribution, molecule types and molecular targets Additional clinical trial analysis by phase, trial size, trial duration and
program failure rate analyses, for each molecule type and mechanism of action Multi-scenario forecasts of the GBM market from 2013 to 2020 in the four APAC
countries An overview of key licensing and co-development agreements that could have an impact on growth trends Analysis of the key drivers and restraints that
have had and are expected to have a significant impact on the market Reasons to Buy
Align your product portfolio to the markets with high growth potential Develop market entry and expansion strategies by identifying the potential regions and
therapeutic segments poised for strong growth Devise a more effectively tailored strategy through the understanding of key drivers and barriers in the GBM
market Develop key strategic initiatives based on an understanding of key focus areas and leading companies Accelerate and strengthen your market position by
identifying key companies for mergers, acquisitions and strategic partnerships
table Of Content
1 Table Of Contents
1.1 List Of Tables
1.2 List Of Figures
2 Glioblastoma Multiforme Therapeutics In Asia-pacific Markets To 2020 – Introduction
2.1 Disease Introduction
2.2 Classification Of Brain Tumors
2.3 Tumor Grading
2.4 Subtypes Of Glioblastoma Multiforme
2.5 Etiology
2.6 Pathophysiology
2.6.1 Loss Of Heterozygosity Of Chromosome 10
2.6.2 Epidermal Growth Factor Receptor Amplification
2.6.3 Phosphatase And Tensin Homolog Mutation
2.6.4 Loss Of P53 Function
2.6.5 P16ink4a Alteration And Loss Of Normal Retinoblastoma 1 Function
2.6.6 Isocitrate Dehydrogenase 1 Or Isocitrate Dehydrogenase 2 Mutation
2.7 Symptoms
2.8 Diagnosis
2.9 Prognosis
2.10 Epidemiology
2.11 Treatment Options
2.11.1 Surgery
2.11.2 Radiation Therapy
2.11.3 Chemotherapy
2.11.4 Targeted Therapy
2.11.5 Drugs For Symptom Relief
2.11.6 Other Alternative Therapies
2.12 Treatment Algorithm
2.13 Gbi Research Report Guidance
Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

2. 3 Glioblastoma Multiforme Therapeutics In Asia-pacific Markets To 2020 – Marketed Products
3.1 Key Marketed Products
3.2 Temodar (temozolomide) – Merck
3.3 Avastin (bevacizumab) – Roche
3.4 Bicnu (carmustine) And Gliadel Wafer (carmustine In Polifeprosan)
3.4.1 Bicnu (carmustine) – Bristol-myers Squibb
3.4.2 Gliadel Wafer (carmustine In Polifeprosan) – Eisai
3.5 Unlicensed/off-label Use In Glioblastoma Multiforme
3.5.1 Lomustine
3.5.2 Carboplatin
3.5.3 Teniposide
3.6 Comparative Efficacy And Safety
3.7 Unmet Needs
4 Glioblastoma Multiforme Therapeutics In Asia-pacific Markets To 2020 – Pipeline
4.1 Overall Pipeline
4.2 Molecular Targets
4.3 Clinical Trials
4.3.1 Clinical Trial Size
4.3.2 Clinical Trial Duration
4.3.3 Failure Rate Of Developmental Pipeline
4.3.4 Summary Of Clinical Trial And Risk Analysis
4.4 Promising Pipeline Candidates
4.4.1 Rindopepimut (cdx-110) – Celldex Therapeutics
4.4.2 Avastin (bevacizumab) – Roche
4.4.3 Cotara – Peregrine Pharmaceuticals
4.4.4 Biomab (nimotuzumab) – Biocon
4.5 Heat Map Of Safety And Efficacy And Product Competitiveness Framework For Glioblastoma Multiforme Pipeline
5 Glioblastoma Multiforme Therapeutics In Asia-pacific Markets To 2020 – Market Forecast To 2020
5.1 Asia-pacific Market
5.1.1 Treatment Use Patterns
5.1.2 Market Size
5.2 Australia
5.2.1 Treatment Use Patterns
5.2.2 Annual Cost Of Therapy
5.2.3 Market Size
5.3 China
5.3.1 Treatment Use Patterns
5.3.2 Annual Cost Of Therapy
5.3.3 Market Size
5.4 India
5.4.1 Treatment Use Patterns
5.4.2 Annual Cost Of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Use Patterns
5.5.2 Annual Cost Of Therapy
5.5.3 Market Size
5.6 Drivers And Barriers For The Glioblastoma Multiforme Therapeutics In The Asia-pacific Market To 2020
5.6.1 Drivers
5.6.2 Barriers
6 Glioblastoma Multiforme Therapeutics In Asia-pacific Markets To 2020 – Deals And Strategic Consolidations
6.1 Major Co-development Deals
6.1.1 Del Mar Pharmaceuticals Enters Into Agreement With Guangxi Wuzhou Pharmaceutical
6.1.2 Immatics Biotechnologies Enters Into Agreement With Cancer Research Uk
6.2 Major Licensing Deals
6.2.1 Eisai Received Marketing Authorization Holder License With Nobelpharma For Gliadel In Japan
6.2.2 Teva Pharma Enters Into Agreement With Perrigo For Generic Temozolomide
6.2.3 Som Biotech Enters Into Licensing Agreement With Argon Pharma For Som0777
6.2.4 Immunocellular Therapeutics Enters Into Agreement With University Of Pennsylvania
6.2.5 Bexion Pharmaceuticals Enters Into Agreement With Cincinnati Children’s Hospital Medical Center
6.2.6 Celldex Therapeutics Enters Into Agreement With Duke University Brain Tumor Cancer Center
Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

3. 7 Glioblastoma Multiforme Therapeutics In Asia-pacific Markets To 2020 – Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Bibliography
7.4 All Pipeline Products By Phase
7.4.1 Discovery
7.4.2 Preclinical
7.4.3 Phase I
7.4.4 Phase Ii
7.4.5 Phase Iii And Pre-registration
7.4.6 Undisclosed Stage Of Development
7.5 Market Forecasts To 2020
7.5.1 Asia-pacific
7.5.2 Australia
7.5.3 China
7.5.4 India
7.5.5 Japan
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Therapeutic Landscape
7.6.4 Forecasting
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Competitive Landscape
7.8 Expert Panel Validation
7.9 Contact Us
7.10 Disclaimer
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM